Dr. Kathryn T. Knight is currently Senior Advisor for PathGroup, having previously served as Medical Director, Cytopathology and Women’s Health. Board-certified in anatomic and clinical pathology as well as cytopathology, Dr. Knight received her medical degree from the University of Mississippi School of Medicine and performed her residency training in Anatomic and Clinical Pathology at Emory University School of Medicine. Dr. Knight subsequently completed a Fellowship in Surgical Pathology at the University of Texas Health Science Center in Dallas. Prior to merging her practice with PathGroup in 2011, Dr. Knight served as Laboratory Medical Director at Hamilton Medical Center in Dalton, Georgia, and President of Associates in Laboratory Medicine. Dr. Knight has been actively involved with the College of American Pathologists, where she currently serves as Speaker of the House of Delegates and as an ex officio member of the Board of Governors.
Search Results for
PathGroup Acquires Pathology Consultants, Continuing Expansion Across the Southeastern United States
NASHVILLE, Tenn.— January 24, 2022 – PathGroup, one of the largest providers of anatomic pathology, digital pathology, clinical and molecular laboratory services in the United States, announced the acquisition of Pathology Consultants, a leading provider of pathology services based in Greenville, S.C.
Click Here to read the press release.
PathGroup Acquires DermLab to Strengthen Dermatopathology Presence in the Southeastern United States
NASHVILLE, Tenn.— August 30, 2021 – PathGroup, one of the largest providers of anatomic pathology, digital pathology, clinical and molecular laboratory services in the United States, announced the acquisition of DermLab, an independent dermatopathology laboratory based in Birmingham, AL. The addition of DermLab is PathGroup’s second dermatology acquisition in 2021 and enhances the company’s dermatopathology capabilities, a key strategic initiative.
Click Here to read the press release.
PathGroup Acquires SkinDx, Expanding Dermatopathology Services
NASHVILLE, June 16, 2021 — PathGroup, one of the largest providers of anatomic pathology, digital pathology, clinical and molecular laboratory services in the United States, announced the acquisition of SkinDx, a leading dermatopathology laboratory in the Southeastern U.S., based in Birmingham, Alabama. This acquisition expands PathGroup’s presence in the dermatopathology space, while also providing state-of-the-art molecular pathology and clinical pathology services for current SkinDx clients.
Click here to read the press release.
Test Announcement: SARS-CoV-2 Antibodies, Spike Protein
February 5, 2021 – PathGroup is pleased to announce the availability of a new serologic test for the detection of human antibodies to the SARS-CoV-2 spike protein (S) receptor binding domain (RBD), the viral pathogen associated with SARS-CoV-2 (COVID-19). The Roche Elecsys® Anti-SARS-CoV-2 S antibody test is for the qualitative and semi-quantitative detection of total antibodies (IgG, IgA and IgM) to SARS-CoV-2 in serum from individuals with prior COVID-19 infection and is intended to aid in identification of patients with an adaptive immune response to SARS-CoV-2 indicating prior infection to the SARS-CoV-2 virus. The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for this test.
Click Here to learn more.
Test Announcement: Combined Influenza and SARS-CoV-2 Testing
Effective today, January 27, 2021, PathGroup is pleased to announce a new multiplex nucleic acid amplification molecular diagnostic test (NAAT) for Influenza A/B & SARS-CoV-2 on the Roche cobas® instrument. This real time RT-PCR based assay is intended for the simultaneous qualitative detection and differentiation of Influenza A virus, Influenza B virus, and/or SARS-CoV-2 RNA from appropriately collected specimens from individuals suspected of associated respiratory viral infection. This test has been issued an Emergency Use Authorization (EUA) by the FDA.
Click here to learn more.
2021 CPT Code Updates
The American Medical Association makes updates to the Current Procedural Terminology (CPT) codes each year. Effective January 1, 2021, there will be CPT code changes for laboratory tests and/or components of tests provided by PathGroup.
Click here to learn more.
2021 ICD Updates
Effective October 1, 2020, the 2021 ICD-10-CM updates for patient encounters occurring October 1, 2020 through September 30, 2021 went into effect.
Click here to learn more.
Test Update: Phospholipase A2 Receptor (PLA2R)
Effective September 23, 2020, PathGroup will discontinue the use of test Phospholipase A2 Receptor Antibodies and replace it with Phospholipase A2 Receptor Antibody, IgG (Test Code: PLA2R).
Click here to learn more.
Test Update: Cystine, Urine (CYSTE)
Effective immediately, PathGroup will discontinue Cystine, Urine Random (Test Code: CYSTE) and replace it with Cystine (Quantitative), 24 Hour Urine (Test CodeL CYSQTU).
Click here to learn more.